MDGL
MDGL
US5588681057
Madrigal Pharmaceuticals, Inc.
Loading chart...

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Latest News

Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus
MDGL
Madrigal Pharmaceuticals (MDGL) Stock Trades At A Discount Following A Very Large 5 Year Run
MDGL
Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?
MDGL
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
LLYMDGLNVO
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
MDGL
MDGL

Related stocks

CAI
CAI • United States
Caris Life Sciences, Inc.
29.7 USD
8.39B USD 1Y -16.5%
MANE
MANE • United States
Veradermics, Incorporated
130.9 USD
5.47B USD
BLTE
BLTE • United States
Belite Bio, Inc
154.49 USD
6.22B USD 1Y +95.4%
SMMT
SMMT • United States
Summit Therapeutics Inc.
17.59 USD
14.03B USD 1Y -26.4%
PBLS
PBLS • United States
Parabilis Medicines, Inc.
27.48 USD
3.39B USD
IBRX
IBRX • United States
ImmunityBio, Inc.
10.51 USD
11.14B USD 1Y +291.7%
PVLA
PVLA • United States
Palvella Therapeutics, Inc.
138.77 USD
2B USD 1Y +75.5%
GENB
GENB • United States
Generate Biomedicines, Inc.
14.34 USD
1.84B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics
Country
United States
Region
North America
Sector
Healthcare
Industry
Biotechnology
Website
https://www.madrigalpharma.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
133.4% p.a.
Max Drawdown (5Y)
-61.4%
Sharpe Ratio (5Y)
0.30
Beta Factor
-1.05
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 High valuation risk: Avg P/E of 49.0 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (133.4% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -82.2% in the extended horizon.
ende